Esophageal Cancer Clinical Trial

Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)

Summary

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in:

participants with esophageal squamous cell carcinoma (ESCC),
participants whose tumors express Programmed Death-Ligand 1 (immunotherapy-drugs-are-boosting-survival/" >PD-L1) Combined Positive Score (CPS) ≥10, and
all participants.

The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:

OS in participants with ESCC,
OS in participants whose tumors express PD-L1 CPS ≥10,
OS in all participants,
EFS in participants with ESCC,
EFS in participants whose tumors express PD-L1 CPS ≥10, and
EFS in all participants.

View Full Description

Full Description

Participants receive pembrolizumab or placebo PLUS one of two chemotherapy regimens PLUS radiation therapy for up to approximately one year. The chemotherapy regimens are either:

FP (5-fluorouracil [5-FU] + cisplatin) or
FOLFOX (5-FU + oxaliplatin + leucovorin or levoleucovorin).

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Has histologically or cytologically confirmed diagnosis of CTX N+ M0 or cT2-T4a NX M0 ESCC, GEJC, EAC, or histologically or cytologically confirmed diagnosis of cTX N+ M1 cervical or upper thoracic esophageal carcinoma with supraclavicular lymph node metastases only
Is deemed suitable for dCRT
Is ineligible for curative surgery based on the documented opinion of a qualified medical/surgical/radiation oncologist
Is not expected to require tumor resection during the course of the study
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 within 3 days of the first dose of study treatment.
Has adequate organ function
Male participants must use adequate contraception (a male condom plus partner use of an additional contraceptive method) unless confirmed to be azoospermic (vasectomized or secondary to medical cause) and refrain from donating sperm during the study treatment period and through 90 days after the last dose of chemotherapy.
Female participants who are a Woman of Childbearing Potential (WOCBP) must use contraception that is highly effective (with a failure rate of <1% per year), with low user dependency, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle, during the study treatment period through 180 days after the last dose of chemotherapy or 120 days after the last dose of pembrolizumab, whichever is greater, and agree not to donate eggs to others or freeze/store for her own use for the purpose of reproduction during this period
Female participants must not be pregnant or breastfeeding

Exclusion Criteria:

Has direct invasion of tumor into adjacent organs such as the aorta or trachea or has radiographic evidence of >90 degree encasement or invasion of a major blood vessel, or of intratumoral cavitation.
Has had major surgery other than for insertion of a feeding tube, open biopsy, or significant traumatic injury within 28 days prior to randomization, or anticipates the need for major surgery during study treatment; participants with gastric or esophageal fistulae are excluded
Has had weight loss of >20% in the previous 3 months
Has had prior chemotherapy or radiotherapy for esophageal cancer
Has had a myocardial infarction within the past 6 months
Has symptomatic congestive heart failure
Has received prior therapy with an anti-programmed cell death-1 (anti PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-programmed cell death-ligand 2 (anti-PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137)
Has received a live or live-attenuated vaccine within 30 days prior to the first dose of study intervention; administration of killed vaccines is allowed
Has received any prior systemic anticancer therapy for esophageal cancer including investigational agents
Has not recovered from all adverse events (AEs) due to previous non-anticancer therapies to ≤Grade 1 or Baseline
Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study treatment
Has a known additional malignancy that is progressing or has required active treatment within the past 3 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, or carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded from the study. Participants with localized prostate cancer that has undergone potentially curative treatment can be enrolled in the study.
Has severe hypersensitivity (≥Grade 3) to pembrolizumab, any of the study chemotherapy agents, or their excipients
Has an active autoimmune disease that has required systemic treatment in past 2 years
Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis
Has an active infection requiring systemic therapy
Has a known history of human immunodeficiency virus (HIV) infection
Has a known history of Hepatitis B or known active Hepatitis C virus infection
Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
Is pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment (180 days for participants receiving cisplatin who are breastfeeding)
Has had an allogenic tissue/solid organ transplant

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

600

Study ID:

NCT04210115

Recruitment Status:

Recruiting

Sponsor:

Merck Sharp & Dohme LLC

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 150 Locations for this study

See Locations Near You

MemorialCare Health System - Long Beach Medical Center-Oncology ( Site 0691)
Long Beach California, 90806, United States More Info
Study Coordinator
Contact
562-933-7866
Columbus Regional Research Institute ( Site 0047)
Columbus Georgia, 31904, United States More Info
Study Coordinator
Contact
706-660-6449
University of Kansas Cancer Center ( Site 0023)
Westwood Kansas, 66205, United States More Info
Study Coordinator
Contact
913-588-2012
Cancer Center of Kansas ( Site 0058)
Wichita Kansas, 67214, United States More Info
Study Coordinator
Contact
316-613-4313
University Medical Center ( Site 0035)
New Orleans Louisiana, 70112, United States More Info
Study Coordinator
Contact
504-702-3574
Greater Baltimore Medical Center ( Site 0031)
Baltimore Maryland, 21204, United States More Info
Study Coordinator
Contact
443-849-3122
Dana Farber Cancer Center ( Site 0034)
Boston Massachusetts, 02215, United States More Info
Study Coordinator
Contact
617-632-5960
Henry Ford Hospital ( Site 0685)
Detroit Michigan, 48202, United States More Info
Study Coordinator
Contact
313-916-0482
University of Missouri ( Site 0688)
Columbia Missouri, 65212, United States
Rutgers Cancer Institute of New Jersey ( Site 0695)
New Brunswick New Jersey, 08903, United States More Info
Study Coordinator
Contact
732-757-9840
Weill Cornell Medical College ( Site 0053)
New York New York, 10065, United States More Info
Study Coordinator
Contact
646-962-6200
Stephenson Cancer Center ( Site 0044)
Oklahoma City Oklahoma, 73104, United States More Info
Study Coordinator
Contact
405-271-8001
Oregon Health & Science University Center for Health & Healing 2- CHH2 ( Site 0060)
Portland Oregon, 97239, United States More Info
Study Coordinator
Contact
503-494-1080
Allegheny Health Network ( Site 0042)
Pittsburgh Pennsylvania, 15212, United States More Info
Study Coordinator
Contact
412-578-1035
Thompson Cancer Survival Center ( Site 0696)
Knoxville Tennessee, 37916, United States More Info
Study Coordinator
Contact
865-331-1678
Cancer Care Northwest - Spokane Valley ( Site 0036)
Spokane Valley Washington, 99216, United States
University of Wisconsin Hospital and Clinics ( Site 0033)
Madison Wisconsin, 53792, United States More Info
Study Coordinator
Contact
608-265-2789
Instituto Medico Alexander Fleming ( Site 0063)
Buenos Aires Caba, , Argentina More Info
Study Coordinator
Contact
+54 11 3221 8900
Fundacion Favaloro ( Site 0061)
Ciudad de Buenos Aires Caba, C1093, Argentina More Info
Study Coordinator
Contact
+5411437812001701
Hospital Municipal de Gastroenterologia Dr. Bonorino Udaondo ( Site 0066)
Buenos Aires , C1264, Argentina More Info
Study Coordinator
Contact
+541143043202
CEMIC ( Site 0064)
Buenos Aires , C1431, Argentina More Info
Study Coordinator
Contact
+541152990100
UCL Saint Luc ( Site 0162)
Brussels Bruxelles-Capitale, Region De, 1200, Belgium More Info
Study Coordinator
Contact
003227641274
UZ Gent ( Site 0163)
Gent Oost-Vlaanderen, 9000, Belgium More Info
Study Coordinator
Contact
+3293329500
UZ Leuven ( Site 0161)
Leuven Vlaams-Brabant, 3000, Belgium More Info
Study Coordinator
Contact
+3216344218
AZ Delta ( Site 0165)
Roeselare West-Vlaanderen, 8800, Belgium More Info
Study Coordinator
Contact
+3251237215
ONCOSITE - Centro de Pesquisa Clinica em Oncologia ( Site 0088)
Ijui Rio Grande Do Sul, 98700, Brazil More Info
Study Coordinator
Contact
+555531950504
Hospital Nossa Senhora da Conceicao ( Site 0087)
Porto Alegre Rio Grande Do Sul, 91350, Brazil More Info
Study Coordinator
Contact
+5551993590437
Clinica de Oncologia Reichow ( Site 0085)
Blumenau Santa Catarina, 89010, Brazil More Info
Study Coordinator
Contact
+554733805858
Instituto do Cancer do Estado de Sao Paulo - ICESP ( Site 0081)
Sao Paulo , 01246, Brazil More Info
Study Coordinator
Contact
551138932686
Cross Cancer Institute ( Site 0010)
Edmonton Alberta, T6G 1, Canada More Info
Study Coordinator
Contact
780-5778072
CancerCare Manitoba ( Site 0002)
Winnipeg Manitoba, R3E 0, Canada More Info
Study Coordinator
Contact
(204) 787-4156
The Ottawa Hospital - Cancer Care ( Site 0008)
Ottawa Ontario, K1H 8, Canada More Info
Study Coordinator
Contact
6137377700
Sunnybrook Research Institute ( Site 0012)
Toronto Ontario, M4N 3, Canada More Info
Study Coordinator
Contact
4164804928
Princess Margaret Cancer Centre ( Site 0011)
Toronto Ontario, M5G 2, Canada More Info
Study Coordinator
Contact
4169466508
Centre Hospitalier de l Universite de Montreal - CHUM ( Site 0005)
Montreal Quebec, H2X 0, Canada More Info
Study Coordinator
Contact
5148908000
Centro Investigación del Cáncer James Lind ( Site 0106)
Temuco Araucania, 48008, Chile More Info
Study Coordinator
Contact
+56994443272
Centro de Investigacion y desarrollo Oncologico SpA - CIDO SpA ( Site 0103)
Temuco Araucania, 48102, Chile More Info
Study Coordinator
Contact
56957983173
Hospital Regional de Concepcion ( Site 0105)
Concepcion Biobio, 40700, Chile More Info
Study Coordinator
Contact
+56992567286
Centro de Cancer Nuestra Senora de la Esperanza ( Site 0104)
Santiago Region M. De Santiago, 83300, Chile More Info
Study Coordinator
Contact
+56991612199
Anhui Provincial Hospital-Oncology Radiotherapy Department ( Site 0531)
Hefei Anhui, 23007, China More Info
Study Coordinator
Contact
+8618202269589
The 900th Hospital of the Joint Logistics Support Force of the Chinese People's Liberation Army ( Si
Fuzhou Fujian, 35002, China More Info
Study Coordinator
Contact
+8613774562945
The First Affiliated Hospital of Xiamen University ( Site 0538)
Xiamen Fujian, 36100, China More Info
Study Coordinator
Contact
86 13806000926
Hubei Cancer Hospital ( Site 0514)
Wuhan Hubei, 43007, China More Info
Study Coordinator
Contact
13907174495
Hunan Cancer Hospital ( Site 0515)
Changsha Hunan, 41000, China More Info
Study Coordinator
Contact
+8613973135460
Huai an First People s Hospital ( Site 0526)
Huai An Jiangsu, 22300, China
Jiangsu Cancer Hospital ( Site 0519)
Nanjing Jiangsu, 21000, China More Info
Study Coordinator
Contact
+8613601458518
The Affiliated Hospital of Xuzhou Medical University ( Site 0522)
Xuzhou Jiangsu, 22100, China More Info
Study Coordinator
Contact
15895236960
Affiliated Hospital of Jiangsu University ( Site 0524)
Zhenjiang Jiangsu, 21200, China
Jiangxi Cancer Hospital ( Site 0512)
Nanchang Jiangxi, 33002, China More Info
Study Coordinator
Contact
0791-88313632
Shanghai Chest Hospital ( Site 0503)
Shangai Shanghai, 20003, China More Info
Study Coordinator
Contact
021-22200000
Shanghai Chest Hospital ( Site 0501)
Shanghai Shanghai, 20003, China More Info
Study Coordinator
Contact
021-22200000
Zhongshan Hospital Fudan University ( Site 0502)
Shanghai Shanghai, 20003, China More Info
Study Coordinator
Contact
+86 13817076800
Sichuan Cancer Hospital ( Site 0527)
Chengdu Sichuan, 61004, China More Info
Study Coordinator
Contact
+8618908178818
Tianjin Medical University Cancer Institute & Hospital ( Site 0505)
Tianjin Tianjin, 30006, China More Info
Study Coordinator
Contact
+02223340123
Hangzhou First People's Hospital ( Site 0530)
Hangzhou Zhejiang, 31000, China More Info
Study Coordinator
Contact
+8613505710131
Sir Run Run Shaw Hospital ( Site 0523)
Hangzhou Zhejiang, 31001, China More Info
Study Coordinator
Contact
+8657186090073
Zhejiang Cancer Hospital ( Site 0529)
Hangzhou Zhejiang, 31002, China More Info
Study Coordinator
Contact
13777461935
Rigshospitalet ( Site 0199)
Copenhagen Hovedstaden, 2100, Denmark More Info
Study Coordinator
Contact
+4535450818
Odense Universitetshospital ( Site 0200)
Odense Syddanmark, 5000, Denmark More Info
Study Coordinator
Contact
+4540467104
SA Pohja-Eesti Regionaalhaigla ( Site 0201)
Tallinn Harjumaa, 13419, Estonia More Info
Study Coordinator
Contact
+3726171245
SA Tartu Ulikooli Kliinikum ( Site 0202)
Tartu Tartumaa, 51014, Estonia More Info
Study Coordinator
Contact
+3727318815
Institut De Cancerologie De Lorraine ( Site 0222)
Vandoeuvre les Nancy Ain, 54519, France More Info
Study Coordinator
Contact
+33383598332
Centre Francois Baclesse ( Site 0236)
Caen Calvados, 14076, France More Info
Study Coordinator
Contact
+550231455419
Centre Georges Francois Leclerc ( Site 0223)
Dijon Cote-d Or, 21079, France More Info
Study Coordinator
Contact
+33345348051
CHU Limoges Hopital Dupuytren ( Site 0225)
Limoges Haute-Vienne, 87042, France More Info
Study Coordinator
Contact
+33555056267
Institut Curie - Centre Rene Huguenin ( Site 0237)
Saint-Cloud Hauts-de-Seine, 92210, France More Info
Study Coordinator
Contact
+33 1 47 11 15 15
CHU Hotel Dieu Nantes ( Site 0230)
Nantes Pays-de-la-Loire, 44093, France More Info
Study Coordinator
Contact
+33244768398
Institut Sainte Catherine ( Site 0228)
Avignon Provence-Alpes-Cote-d Azur, 84918, France More Info
Study Coordinator
Contact
+33490276268
CHU Amiens Picardie Site Sud Amiens ( Site 0235)
Amiens Somme, 80054, France More Info
Study Coordinator
Contact
+33322088854
CHD Vendee ( Site 0227)
La Roche sur Yon Vendee, 85925, France More Info
Study Coordinator
Contact
+0033251446161
Marienhospital Stuttgart Vincenz von Paul Kliniken gGmbH ( Site 0253)
Stuttgart Baden-Wurttemberg, 70199, Germany More Info
Study Coordinator
Contact
+4971164898107
Universitaetsklinikum Koeln ( Site 0251)
Koeln Nordrhein-Westfalen, 50937, Germany More Info
Study Coordinator
Contact
+4922147887009
Universitaetsklinikum Muenster ( Site 0248)
Muenster Nordrhein-Westfalen, 48149, Germany More Info
Study Coordinator
Contact
+492518352712
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz ( Site 0247)
Mainz Rheinland-Pfalz, 55131, Germany More Info
Study Coordinator
Contact
+496131176076
Charite Campus Virchow Klinikum ( Site 0250)
Berlin , 13353, Germany More Info
Study Coordinator
Contact
00493045050
Facharztzentrum Eppendorf ( Site 0242)
Hamburg , 20249, Germany More Info
Study Coordinator
Contact
00494036035220
Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 0122)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50222783107
Gastrosoluciones ( Site 0126)
Guatemala , 01010, Guatemala
Oncomedica ( Site 0125)
Guatemala , 01010, Guatemala More Info
Study Coordinator
Contact
+50256973689
Grupo Medico Angeles ( Site 0121)
Guatemala , 01015, Guatemala More Info
Study Coordinator
Contact
+50240492110
Medi-K Cayala ( Site 0124)
Guatemala , 01016, Guatemala More Info
Study Coordinator
Contact
+50255505555
Centro Medico Integral De Cancerología (CEMIC) ( Site 0123)
Quetzaltenango , 09002, Guatemala More Info
Study Coordinator
Contact
+50259458053
Pamela Youde Nethersole Eastern Hospital ( Site 0543)
Hong Kong , , Hong Kong More Info
Study Coordinator
Contact
+85225954183
Princess Margaret Hospital. ( Site 0542)
Hong Kong , , Hong Kong More Info
Study Coordinator
Contact
+85229902393
Queen Mary Hospital ( Site 0541)
Pokfulam , , Hong Kong More Info
Study Coordinator
Contact
22554216
Pecsi Tudomanyegyetem AOK ( Site 0265)
Pecs Baranya, 7624, Hungary More Info
Study Coordinator
Contact
+3672536000
Bekes Megyei Kozponti Korhaz - Pandy Kalman Tagkorhaza ( Site 0262)
Gyula Bekes, 5700, Hungary
Orszagos Onkologiai Intezet ( Site 0263)
Budapest , 1122, Hungary More Info
Study Coordinator
Contact
+3612248600
Debreceni Egyetem Klinikai Kozpont ( Site 0261)
Debrecen , 4032, Hungary More Info
Study Coordinator
Contact
+3652255840
Fondazione IRCCS Policlinico San Matteo-Oncology ( Site 0300)
Pavia Lombardia, 27100, Italy More Info
Study Coordinator
Contact
+39 0382503689
IRCCS Policlinico San Donato ( Site 0295)
San Donato Milanese Milano, 20097, Italy
Azienda Ospedaliero Universitaria Pisana - Presidio Santa Chiara ( Site 0294)
Pisa Toscana, 56126, Italy More Info
Study Coordinator
Contact
+39050993841
ASST Papa Giovanni XXIII ( Site 0296)
Bergamo , 24127, Italy
Azienda Socio Sanitaria Territoriale di Cremona ( Site 0299)
Cremona , 26100, Italy More Info
Study Coordinator
Contact
+390372405242
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano ( Site 0292)
Milano , 20133, Italy More Info
Study Coordinator
Contact
+390223902882
Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Oncologia Clinica Sperimentale Addome ( Site 0
Napoli , 80131, Italy More Info
Study Coordinator
Contact
0815903629
IRCCS Istituto Oncologico Veneto ( Site 0298)
Padova , 35128, Italy More Info
Study Coordinator
Contact
+390498215910
Policlinico Universitario A. Gemelli ( Site 0297)
Roma , 00168, Italy More Info
Study Coordinator
Contact
+390696734844
Aichi Cancer Center Hospital ( Site 0563)
Nagoya Aichi, 464-8, Japan More Info
Study Coordinator
Contact
+81527626111
National Cancer Center Hospital East ( Site 0562)
Kashiwa Chiba, 27785, Japan More Info
Study Coordinator
Contact
+81471331111
Kanagawa Cancer Center ( Site 0565)
Yokohama Kanagawa, 241-8, Japan More Info
Study Coordinator
Contact
+81455202222
Saitama Cancer Center ( Site 0564)
Kitaadachi-gun Saitama, 362-0, Japan More Info
Study Coordinator
Contact
+81487221111
Shizuoka Cancer Center Hospital and Research Institute ( Site 0566)
Sunto-gun Shizuoka, 411-8, Japan More Info
Study Coordinator
Contact
+81559895222
National Cancer Center Hospital ( Site 0561)
Tokyo , 104-0, Japan More Info
Study Coordinator
Contact
+81335422511
Chonnam National University Hwasun Hospital ( Site 0625)
Hwasun Gun Jeonranamdo, 58128, Korea, Republic of More Info
Study Coordinator
Contact
+8218990000
National Cancer Center ( Site 0626)
Goyang-si Kyonggi-do, 10408, Korea, Republic of
Asan Medical Center ( Site 0623)
Songpagu Seoul, 05505, Korea, Republic of More Info
Study Coordinator
Contact
+8216887575
Severance Hospital Yonsei University Health System ( Site 0624)
Seoul , 03722, Korea, Republic of More Info
Study Coordinator
Contact
+82 2 2228 1004
Samsung Medical Center ( Site 0622)
Seoul , 06351, Korea, Republic of More Info
Study Coordinator
Contact
+82215993114
Korea University Guro Hospital ( Site 0621)
Seoul , 08308, Korea, Republic of More Info
Study Coordinator
Contact
+8215779966
Instituto Nacional de Enfermedades Neoplasicas ( Site 0141)
Lima Muni Metro De Lima, Lima , Peru
Hospital Nacional Arzobispo Loayza ( Site 0143)
Lima , 15082, Peru More Info
Study Coordinator
Contact
+51987421693
Clinica San Gabriel ( Site 0142)
Lima , 15087, Peru
Baguio General Hospital and Medical Center ( Site 0603)
Baguio City Benguet, 2600, Philippines More Info
Study Coordinator
Contact
+639985529020
Cebu Doctors University Hospital ( Site 0604)
Cebu City Cebu, 6000, Philippines More Info
Study Coordinator
Contact
+63322386248
The Medical City-Iloilo ( Site 0602)
Iloilo City Iloilo, 5000, Philippines More Info
Study Coordinator
Contact
+639228372408
St. Luke s Medical Center ( Site 0601)
Quezon National Capital Region, 1102, Philippines More Info
Study Coordinator
Contact
+639175431178
Hospital Beatriz Angelo ( Site 0374)
Loures Lisboa, 2674-, Portugal More Info
Study Coordinator
Contact
+351219847200
Inst. Portugues de Oncologia de Lisboa Francisco Gentil EPE ( Site 0372)
Lisboa , 1099-, Portugal More Info
Study Coordinator
Contact
+351217229800
CHLN Hospital Santa Maria ( Site 0376)
Lisboa , 1649-, Portugal More Info
Study Coordinator
Contact
+351217805000
Inst. Portugues de Oncologia de Porto Francisco Gentil EPE ( Site 0371)
Porto , 4200-, Portugal More Info
Study Coordinator
Contact
+351225084000
MedEuropa Bucuresti - Centru de Radioterapie-Oncology ( Site 0400)
București Bucuresti, 02234, Romania More Info
Study Coordinator
Contact
+40727824017
Institutul Oncologic Prof.Dr. Ion Chiricuta Cluj-Napoca ( Site 0392)
Cluj-Napoca Cluj, 40001, Romania More Info
Study Coordinator
Contact
+40264598361
S.C. Radiotherapy Center Cluj S.R.L ( Site 0391)
Cluj-Napoca Cluj, 40728, Romania More Info
Study Coordinator
Contact
+40742206212
S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 0394)
Craiova Dolj, 20034, Romania More Info
Study Coordinator
Contact
+40727774974
Centrul Medical Topmed ( Site 0398)
Targu-Mures Mures, 54015, Romania More Info
Study Coordinator
Contact
+40740277907
S.C.Focus Lab Plus S.R.L ( Site 0395)
Bucuresti , 02254, Romania More Info
Study Coordinator
Contact
+40721298677
Spitalul Clinic Judetean De Urgenta Constanta ( Site 0393)
Constanta , 90059, Romania More Info
Study Coordinator
Contact
+40241503485
GBUZ Republican Clinical Oncological Dispensary-Antitumor drug therapy department ( Site 0430)
Ufa Baskortostan, Respublika, 45005, Russian Federation
Kaluga Regional Clinical Oncology Center ( Site 0424)
Kaluga Kaluzskaja Oblast, 24800, Russian Federation
Main Military Clinical Hospital n.a. N.N.Burdenko ( Site 0421)
Moscow Moskva, 10522, Russian Federation
FSAI Treatment and Rehabilitation Centre of the MoH and SD of RF ( Site 0429)
Moscow Moskva, 12536, Russian Federation
SBHI Samara Regional Clinical Oncology Dispensary ( Site 0420)
Samara Samarskaya Oblast, 44303, Russian Federation
Pavlov First Saint Petersburg State Medical University ( Site 0426)
St. Petersburg Sankt-Peterburg, 19702, Russian Federation
Medical institute named after Berezin Sergey ( Site 0417)
St. Petersburg Sankt-Peterburg, 19775, Russian Federation
Sverdlovsk Regional Oncology Hospital ( Site 0411)
Ekaterinburg Sverdlovskaya Oblast, 62003, Russian Federation
Republican Clinical Oncology Dispensary of Tatarstan MoH ( Site 0412)
Kazan Tatarstan, Respublika, 42002, Russian Federation
Chang Gung Med Foundation. Kaohsiung Branch ( Site 0643)
Kaohsiung , 833, Taiwan More Info
Study Coordinator
Contact
+88677317123
China Medical University Hospital ( Site 0646)
Taichung , 40447, Taiwan More Info
Study Coordinator
Contact
+886422052121
Taichung Veterans General Hospital-Radiation Oncology ( Site 0647)
Taichung , 407, Taiwan More Info
Study Coordinator
Contact
+886423592525
National Cheng Kung University Hospital ( Site 0645)
Tainan , 704, Taiwan More Info
Study Coordinator
Contact
+88662353535
National Taiwan University Hospital ( Site 0641)
Taipei , 10048, Taiwan More Info
Study Coordinator
Contact
+886223123456
Koo Foundation Sun Yat-Sen Cancer Center ( Site 0644)
Taipei , 11259, Taiwan More Info
Study Coordinator
Contact
+886228970011
Chang Gung Medical Foundation. Linkou ( Site 0642)
Taoyuan , 33305, Taiwan
İstanbul University Cerrahpaşa Medical Faculty ( Site 0452)
Istambul Istanbul, 34098, Turkey More Info
Study Coordinator
Contact
+905324167355
Memorial Ankara Hastanesi ( Site 0461)
Ankara , 06520, Turkey More Info
Study Coordinator
Contact
+905067521275
Göztepe Prof. Dr. Süleyman Yalçın Şehir Hastanesi-oncology ( Site 0451)
Istanbul , 34722, Turkey More Info
Study Coordinator
Contact
+902166065200
Ege Universitesi Tip Fakultesi ( Site 0457)
Izmir , 35040, Turkey More Info
Study Coordinator
Contact
+905325566065
Izmir Katip Celebi Universitesi Ataturk Egitim ve Arastirma Hastanesi ( Site 0458)
Izmir , 35360, Turkey More Info
Study Coordinator
Contact
+905324078648
Aberdeen Royal Infirmary ( Site 0474)
Aberdeen Aberdeen City, AB25 , United Kingdom More Info
Study Coordinator
Contact
441224550061
Cambridge University Hospitals NHS Trust ( Site 0477)
Cambridge Cambridgeshire, CB2 0, United Kingdom More Info
Study Coordinator
Contact
+441223216083
Royal Free Hospital ( Site 0702)
London England, NW32Q, United Kingdom More Info
Study Coordinator
Contact
+442077940500
ROYAL MARSDEN HOSPITAL (CHELSEA) ( Site 0283)
London London, City Of, SW3 6, United Kingdom More Info
Study Coordinator
Contact
+442086426011
Hammersmith Hospital-Medical Oncology ( Site 0471)
London London, City Of, W12 0, United Kingdom More Info
Study Coordinator
Contact
+44 20 3312 6666
Nottingham University Hospitals NHS Trust ( Site 0476)
Nottingham Nottinghamshire, NG5 1, United Kingdom More Info
Study Coordinator
Contact
441159691169
Royal Marsden Hospital (Sutton) ( Site 0281)
Sutton Surrey, SM2 5, United Kingdom More Info
Study Coordinator
Contact
+4473528171
University College Hospital NHS Foundation Trust ( Site 0701)
London Worcestershire, NW1 2, United Kingdom More Info
Study Coordinator
Contact
0203 447 9093
The Christie NHS Foundation Trust ( Site 0282)
Manchester , M20 4, United Kingdom More Info
Study Coordinator
Contact
+4401614463209
Mount Vernon Hospital ( Site 0478)
Northwood , HA6 2, United Kingdom More Info
Study Coordinator
Contact
+447469141803

How clear is this clinincal trial information?

Study is for people with:

Esophageal Cancer

Phase:

Phase 3

Estimated Enrollment:

600

Study ID:

NCT04210115

Recruitment Status:

Recruiting

Sponsor:


Merck Sharp & Dohme LLC

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.